Anti-Obesity Compound Library

Description: Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.
MCE Anti-Obesity Compound Library owns a unique collection of 2338 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.
MCE Anti-Obesity Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 2290 compounds supplied in 10 mM solution, 45 compounds supplied in 2 mM solution and 3 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 2338 obesity related compounds.
• The major targets include Fatty Acid Synthase, DGAT, Acetyl-CoA Carboxylas, MCHR1 (GPR24), Stearoyl-CoA Desaturase (SCD), etc..
• A useful tool for the discovery of anti-obesity drugs.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• High purity validated by NMR and LC/MS.
• All compounds are in stock and continuously updated.

Formulation: A collection of 2338 anti-obesity compounds supplied as pre-dissolved Solutions or Solid.Solution:2290 compounds supplied in 10 mM solution,45 compounds supplied in 2 mM solution,3 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L087-100
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L087-100
• Green Labware: Nein
• Verpackungseinheit: 100 μl
• Mengeneinheit: STK